Estrogenic or antiestrogenic therapies for multiple myeloma?
2007
Estrogenic or antiestrogenic therapies for multiple myeloma?
publication
Evidence: moderate
Author Information
Author(s): Sola Brigitte, Renoir Jack-Michel
Primary Institution: Université de Caen, Caen, France
Hypothesis
Can estrogenic and antiestrogenic compounds be effective treatments for multiple myeloma?
Conclusion
Estrogenic and antiestrogenic compounds can inhibit the growth of multiple myeloma cells and may provide a new therapeutic strategy.
Supporting Evidence
- Estrogenic compounds inhibit cell proliferation in multiple myeloma cells.
- These compounds induce apoptosis in drug-resistant multiple myeloma cells.
- Estrogenic therapies can enhance the effects of conventional drugs.
- 2-methoxyestradiol has shown antiangiogenic properties in xenograft models.
Takeaway
Some medicines that act like estrogen can help fight a type of blood cancer called multiple myeloma by stopping the cancer cells from growing.
Methodology
The review discusses preclinical studies of 2-methoxyestradiol, SERDs, and SERMs in multiple myeloma.
Limitations
The review is based on preclinical studies, and clinical efficacy in patients is yet to be established.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website